Why Enovis (ENOV) Stock Is Trading Up Today
Enovis (ENOV) stock jumped 15% after the Centers for Medicare & Medicaid Services reversed prior reimbursement cuts for the company's non-invasive bone growth stimulators. This decision, along with broader healthcare sector strength, significantly impacted the market's perception of the business. The stock had previously declined and is currently down 3% year-to-date.
Enovis shares jump after Medicare reverses reimbursement cuts
Enovis Corp shares rose approximately 11% following Medicare's reversal of previously announced reimbursement cuts for the company’s non-invasive bone growth stimulators. The decision by the Centers for Medicare & Medicaid Services positively impacted the company's stock. This article was generated with the support of AI and reviewed by an editor.
Enovis (ENOV) director Christine Ortiz receives 846-share stock award
Enovis (ENOV) director Christine Ortiz was granted 846 shares of common stock on June 30, 2026, as a compensation-related award with a stated price of $0.00 per share. This transaction increased her direct holdings to 25,857 shares of Enovis common stock. The Form 4 filing indicates a routine non-derivative stock award, not an open-market purchase or sale.
Form 4 Enovis Corp For: 1 July By Investing.com
This article from Investing.com UK is a Form 4 filing for Enovis Corp, dated July 1st. It provides a brief mention of the company (ENOV) and its stock performance (+12.28%), alongside extensive financial market data and news headlines. The content primarily focuses on market movements and financial updates.
How Investors Are Reacting To Enovis (ENOV) Russell 2000 Defensive Index Removal And Rebalancing
Enovis Corporation (NYSE: ENOV) was removed from the Russell 2000 Defensive and Value-Defensive Indices on June 27, 2026, which may lead to short-term trading volatility as index-tracking funds rebalance. The article notes that this removal does not change Enovis's core strategy of margin improvement and integrating acquisitions, with the company reaffirming its 2026 revenue guidance. Despite current net losses and a goodwill impairment, Enovis projects significant revenue and earnings growth by 2029, suggesting a potential undervaluation based on analyst forecasts.
How Investors Are Reacting To Enovis (ENOV) Russell 2000 Defensive Index Removal And Rebalancing
Enovis Corporation (ENOV) was removed from the Russell 2000 Defensive and Value-Defensive Indices on June 27, 2026, which may impact its investor base and trading volatility. Despite this, the company's core investment narrative remains focused on margin improvement, integrating acquisitions, and achieving its reaffirmed 2026 revenue guidance of US$2.31–US$2.37 billion. Investors are closely watching how Enovis executes on these goals amid ongoing net losses and a recent goodwill impairment.
Enovis stock hits 52-week low at 20.45 USD
Enovis Corporation's stock has fallen to a 52-week low of $20.45, representing a 37.1% decrease over the past year and placing it 44% below its 52-week high. Despite this decline, InvestingPro analysts suggest the stock is undervalued, predicting future profitability and setting price targets between $33 and $55. The company recently reported strong Q1 2026 earnings, launched a new scoliosis brace, and amended its incentive plan, highlighting ongoing strategic initiatives.
Enovis (ENOV) Could Be 46% Undervalued As Net Profit Jumps 84%
Enovis (ENOV) recently reported an 84.34% year-over-year increase in net profit on quarterly revenue of US$589.15 million, suggesting it could be significantly undervalued by 46% according to certain models, trading at US$22.71 against a fair value of US$42.30. Despite a weak year-to-date share price performance, the company's focus on next-generation technologies like Arvis and pipeline innovation in hips, knees, and shoulders positions it for potential growth, though risks from acquisitions and platform rollouts exist.
Enovis (ENOV) Could Be 46% Undervalued As Net Profit Jumps 84%
Enovis (ENOV) has seen an 84.34% year-over-year increase in net profit, despite overall weak financial scores and average operating efficiency. Trading at US$22.71, the company is considered by some models to be significantly undervalued, with a fair value narrative suggesting $42.30, driven by its focus on next-generation technologies like Arvis. However, risks such as integration challenges with recent acquisitions and platform rollout delays could impact this bullish outlook.
Enterprise value to revenue forward of Enovis Corporation – NYSE:ENOV
This article provides a brief financial snippet for Enovis Corporation (NYSE: ENOV), displaying its enterprise value to revenue forward. It indicates the period, value, and change percentages for this financial metric. The content is presented by TradingView and includes standard disclaimers about market data providers.
Enovis Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.25 Sh
This page provides financial actuals and estimates for Enovis Corporation (E2NO34) on the BMFBOVESPA exchange. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. Users can compare actual results with average, high, and low estimates, and visualize trends over time.
Enterprise value to EBITDA forward of Enovis Corporation – NYSE:ENOV
The article focuses on the enterprise value to EBITDA forward for Enovis Corporation (NYSE: ENOV). It appears to be a financial data snippet from TradingView, providing a period, value, and change for this specific financial metric. The content is presented within the context of Enovis Corporation's financial overview on the TradingView platform.
Price to earnings forward of Enovis Corporation – NYSE:ENOV
The article displays the "Price to earnings forward" metric for Enovis Corporation (NYSE: ENOV). It shows that for the displayed period, the value was 'No trades', indicating no recent trading activity for this specific financial metric. The content is primarily a data point presented within a financial charting platform context.
Enovis Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.25 Sh Actuals & Estimates (BMFBOVESPA:E2NO34)
This article provides an overview of Enovis Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.25 Sh (E2NO34) on the BMFBOVESPA exchange, focusing on its financial actuals and estimates. It highlights that users can explore reported financial data and analyst estimates across various financial statements and valuation metrics. The content emphasizes comparing actual results with estimates and visualizing trends.
ENOV - Enovis Corp Short Interest
This article provides a detailed financial overview of Enovis Corp (ENOV), including its last closing price, market capitalization, income, sales, and various financial ratios. It also highlights short interest data, insider and institutional ownership, and stock performance over different periods. The data indicates a significant short float of 16.11% and various performance metrics like a year-to-date decline of -22.30%.
BTIG Maintains Enovis Corp(ENOV.US) With Buy Rating, Maintains Target Price $39
BTIG has reiterated its Buy rating for Enovis Corp (ENOV.US) and maintained its target price at $39. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Enovis Corp (ENOV) Financial Health: Profitability & Balance Sheet Analysis
Enovis Corp (ENOV) has a current financial score of 6.28, placing it 164th out of 204 in the Healthcare Equipment & Supplies industry, indicating weak financial status but average operating efficiency. The company recently reported a quarterly revenue of $589.15M, a 5.43% year-over-year increase, with net profit showing a significant 84.34% year-over-year increase. Despite some key financial data not yet being disclosed, its growth potential and shareholder returns scores are moderately positive.
Enovis Corp (ENOV) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Enovis Corp (ENOV), detailing its current price momentum score, support and resistance levels. It reviews various technical indicators like MACD, RSI, and moving averages, all of which currently suggest a "Sell" signal for the stock. The document also includes FAQs explaining technical ratings and moving averages for investment reference.
ENOV Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Enovis Corp (ENOV), indicating a "Strong Sell" consensus based on various technical indicators and moving averages. The analysis highlights key support and resistance levels, momentum indicators like RSI and MACD, and the stock's performance relative to its 20-day, 60-day, and 200-day moving averages.
Enovis Corp (ENOV) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Enovis Corp (ENOV), highlighting its current earnings forecast score, average price target, and analyst ratings. It includes peer comparisons and answers frequently asked questions regarding revenue expectations, price targets, and past EPS performance. The consensus among 11 analysts is a "Buy" trend for Enovis Corp.
Enovis (ENOV) Q4 2025 earnings summary
Enovis (ENOV) reported a strong financial performance for Q4 and full year 2025, achieving 7% reported and 6% organic sales growth, driven by commercial execution and new product launches across its Reconstructive and Prevention & Recovery segments. The company returned to positive free cash flow, exceeding its cash goals with over 10% conversion. For 2026, Enovis expects continued growth, with revenue guidance of $2.31–$2.37 billion and a target of 25%+ free cash flow conversion.
Enovis (ENOV) Stock Could Be 49.8% Undervalued After Spinamic Brace Launch
Enovis (ENOV) has launched its new DonJoy Spinamic Hybrid Scoliosis Brace, yet the stock has seen an 18.6% year-to-date decline and a 30.1% drop over the last year. Despite this, a common market narrative suggests ENOV is 49.8% undervalued, citing a fair value of $43 per share compared to its current $21.58, based on expectations of future margin improvement and cash generation. However, potential challenges like acquisition integration and launch delays could affect this outlook.
Enovis Corp (ENOV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Enovis Corp (ENOV) by business segment and geographical region. It shows that in USD, the Medical Technology-Prevention & Rehabilitation segment contributes 1.14B (50.58%) and Medical Technology-Reconstructive contributes 1.11B (49.42%). Regionally, the United States accounts for 1.30B (57.62%) of revenue, while other foreign locations contribute 952.72M (42.38%).
Enovis (ENOV) Stock Could Be 49.8% Undervalued After Spinamic Brace Launch
Enovis (ENOV) has launched the DonJoy Spinamic Hybrid Scoliosis Brace, attracting investor attention despite the stock's recent decline. Simply Wall St's analysis suggests Enovis could be 49.8% undervalued at $43 per share, based on future margin improvement and cash generation, compared to its current price of $21.58. However, potential risks like acquisition integration challenges and delayed technology launches could impact these forecasts.
Enovis chief administrative officer Engert buys $20,920 in stock By Investing.com
Enovis's Chief Administrative Officer, Oliver Engert, recently purchased 1,000 shares of the company's stock for $20,920, with shares acquired close to their 52-week low. This insider purchase follows a 30% decline in stock value over the past year, though InvestingPro analysis suggests the stock is undervalued. The company also reported strong Q1 2026 earnings, exceeding forecasts, and launched a new scoliosis brace.
Enovis chief administrative officer Engert buys $20,920 in stock
Enovis Chief Administrative Officer Oliver Engert recently purchased 1,000 shares of the company's common stock for $20,920, with the price of $20.92 per share being close to the stock's 52-week low. This insider purchase occurs as shares have declined 30% over the past year. The company also reported strong Q1 2026 earnings, exceeded revenue expectations, approved an amendment to its Omnibus Incentive Plan, and launched a new scoliosis brace.
Enovis (ENOV) CAO adds 1,000 shares in $20.92 open-market buy
Enovis Corp's Chief Administrative Officer, Oliver Engert, purchased 1,000 shares of company stock at $20.92 per share in an open-market transaction. This acquisition increases his direct ownership to 53,640 shares, signaling his continued confidence in the company. The transaction was reported in a Form 4 SEC filing, detailing the insider trade and the resulting change in his holdings.
Enovis (ENOV) amends Form 4 to reflect 1,000-share stock grant
Enovis Corp.'s Chief Administrative Officer, Oliver Engert, amended his Form 4 filing to correct clerical errors regarding a stock grant. The amendment confirms he received 1,000 shares of common stock at $20.99 per share, bringing his direct holdings to 52,640 shares. The Form 4/A did not introduce new transactions but clarified previously reported details.
Enovis CAO Oliver Engert acquires $25,948 in company stock By Investing.com
Enovis Chief Administrative Officer Oliver Engert recently acquired 1,200 shares of the company's common stock for $25,948, bringing his direct holdings to 51,840 shares. This insider purchase occurred while Enovis stock trades near its 52-week low, though InvestingPro analysis suggests it is undervalued with a "GOOD" financial health rating. The company also reported strong Q1 2026 earnings, launched a new scoliosis brace, and approved an amendment to its Omnibus Incentive Plan.
Enovis CAO Oliver Engert acquires $25,948 in company stock
Enovis Chief Administrative Officer Oliver Engert recently acquired $25,948 worth of company stock through two transactions, purchasing 1,200 shares at prices between $20.99 and $21.75 per share. This insider purchase comes as Enovis (NASDAQ:ENOV) stock trades near its 52-week low, with InvestingPro analysis suggesting it is undervalued. The company recently reported strong Q1 2026 earnings, launched a new scoliosis brace, and had shareholders approve an amendment to its incentive plan.
Enovis CAO Oliver Engert acquires $25,948 in company stock By Investing.com
Enovis's Chief Administrative Officer, Oliver Engert, purchased 1,200 shares of the company's common stock for $25,948, bringing his total direct holdings to 51,840 shares. This insider acquisition comes as the stock trades near its 52-week low and is considered undervalued by InvestingPro analysis, despite the company reporting strong first-quarter 2026 earnings and launching a new product.
Enovis CAO Oliver Engert acquires $25,948 in company stock By Investing.com
Enovis Chief Administrative Officer Oliver Engert recently acquired 1,200 shares of the company's common stock for a total of $25,948, with shares purchased at prices between $20.99 and $21.75. This insider purchase occurs while Enovis stock is trading near its 52-week low and is considered undervalued by InvestingPro, which rates the company's financial health as "GOOD." The company recently reported strong Q1 2026 earnings and launched a new scoliosis brace, and shareholders approved an amendment to its incentive plan.
Enovis (ENOV) CAO Oliver Engert adds 1,200 shares in open-market buys
Enovis CORP's Chief Administrative Officer, Oliver Engert, bought an additional 1,200 shares of the company's common stock through two open-market purchases. The transactions involved 1,000 shares at $21.75 per share and 200 shares at $20.99 per share, totaling $25,948. These direct purchases signal an increased personal stake and positive sentiment from the insider.
Is Enovis (ENOV) Using Spinamic to Quietly Redefine Its Orthopedic Innovation Playbook?
Enovis Corporation (ENOV) recently launched its DonJoy Spinamic Hybrid Scoliosis Brace, aiming to improve patient outcomes and clinic efficiency. This innovation supports Enovis's focus on orthopedic solutions, though the company's main challenge remains narrowing losses and stabilizing earnings, with a 2026 revenue guidance of US$2.31 billion to US$2.37 billion. Investors should consider how new products like Spinamic contribute to the company's long-term profitability and its projected revenue of $2.6 billion and earnings of $121.6 million by 2029.
Enovis chief administrative officer Engert buys $23,000 in stock By Investing.com
Oliver Engert, Chief Administrative Officer at Enovis CORP (NASDAQ:ENOV), purchased 1,000 shares of the company's common stock for $23,000 on June 10, 2026. This transaction occurred while the stock was trading near its 52-week low and is considered undervalued by InvestingPro analysis. Following this acquisition, Engert directly holds 50,640 shares of Enovis common stock.
Enovis stock hits 52-week low at 20.79 USD
Enovis Corp's stock has reached a 52-week low of $20.84, trading just above its lowest point of $20.82. Despite a 35.12% decline over the past year, InvestingPro analysis indicates the stock is undervalued with a Fair Value of $29.81, and net income is projected to grow this year. The company recently reported strong Q1 2026 earnings, launched a new scoliosis brace, and shareholders approved an amendment to its incentive plan.
Insider Buying: Oliver Engert Acquires Shares of Enovis Corp (ENOV)
Oliver Engert, Chief Administrative Officer at Enovis Corp, recently purchased 1,000 shares, increasing his total holdings to 50,640 shares. This transaction is part of a larger trend of insider buying at Enovis Corp over the past year, indicating insider confidence in the company. Despite the insider confidence, the stock's current trading price of $23 is significantly lower than its GF Value of $50.01, suggesting it might be a "Possible Value Trap, Think Twice."
Enovis chief administrative officer Engert buys $23,000 in stock
Enovis's Chief Administrative Officer, Oliver Engert, purchased 1,000 shares of company stock for $23,000. This transaction occurred on June 10, 2026, when the stock was trading near its 52-week low. Engert now directly holds 50,640 shares, and InvestingPro analysis suggests the stock is undervalued.
Enovis (ENOV) CAO Oliver Engert buys 1,000 shares in open market
Enovis Chief Administrative Officer Oliver Engert purchased 1,000 shares of the company's common stock at $23.00 per share on June 10, 2026, in an open-market transaction. This purchase increased his direct ownership to 50,640 shares, signaling increased confidence in the company. The transaction was reported in a Form 4 SEC filing.
Insider Buying: Oliver Engert Acquires Shares of Enovis Corp (ENOV)
Oliver Engert, Chief Administrative Officer at Enovis Corp (ENOV), purchased 1,000 shares of the company, bringing his total holdings to 50,640 shares. This transaction, following a pattern of 12 insider purchases and 1 sale over the past year, suggests insider confidence despite the stock being identified as a "Possible Value Trap" by GuruFocus due to its price relative to its GF Value. The GF Value for ENOV is estimated at $50.01, significantly higher than its trading price of $23 on the day of the purchase.
Medical Devices Specialty Stocks Q1 2026: Enovis Revenue Beat, Stock Down 12% - News and Statistics
A review of Q1 2026 earnings for medical devices and supplies specialty stocks indicates that the sector's average revenue exceeded analyst estimates by 5.2%. Enovis, a key player in orthopedic medical devices, reported a 5.4% year-over-year revenue increase to $589.2 million, surpassing expectations. Despite these positive results and robust execution, Enovis's stock declined by 12% following its earnings report, trading at $21.87, due to the weakest full-year guidance update among its peers and market discontent.
CD&R Appoints Former Enovis CEO Matthew Trerotola as Operating Advisor
Clayton, Dubilier & Rice (CD&R) has appointed Matthew Trerotola, former CEO of Enovis Corporation, as an operating advisor. In this role, Trerotola will leverage his extensive experience in healthcare and industrial sectors to evaluate potential transactions and support the growth initiatives of CD&R's portfolio companies. This appointment highlights private equity's increasing focus on operational expertise for value creation.
CD&R Engages Former Enovis CEO as Operating Advisor — CD&R | Building Businesses Building Value
CD&R has announced that Matthew Trerotola, former Chief Executive Officer of Enovis Corporation, will join the firm as an Operating Advisor. In this role, Trerotola will assist CD&R's healthcare and industrials investment teams in sourcing and evaluating transactions, and support portfolio company management. Trerotola's extensive experience at companies like Enovis, DuPont, and Danaher, where he focused on corporate transformation and innovation, is expected to enhance CD&R's investment strategies in key sectors.
Spotting Winners: Enovis (NYSE:ENOV) And Medical Devices & Supplies - Specialty Stocks In Q1
This article analyzes the Q1 earnings of several medical devices & supplies specialty stocks, focusing on top performers like Enovis, STAAR Surgical, and others. It discusses the industry's business model, challenges from regulatory compliance and pricing pressures, and tailwinds such as an aging population and advancements in digital health. The report provides detailed revenue performance and analyst expectations for each featured company.
Enovis launches hybrid scoliosis brace in U.S. market
Enovis Corporation has launched the DonJoy Spinamic Hybrid Scoliosis Brace in the U.S., designed to treat adolescent idiopathic scoliosis. This device combines rigid corrective elements with a flexible mesh design, offering a more comfortable and efficient treatment option. Despite a recent 25% stock decline, Enovis shares rose nearly 10% this past week, and analysts predict profitability for the company this year.
Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining
Enovis Corporation has launched the DonJoy Spinamic® Hybrid Scoliosis Brace, designed to offer an optimal balance of corrective performance and improved wearability for children and teens with adolescent idiopathic scoliosis (AIS). This innovative brace integrates rigid corrective elements into a breathable, adjustable design, aiming to enhance clinical outcomes and patient compliance. Available in 10 off-the-shelf sizes, the brace allows for fitting, imaging, and adjustment in a single visit, addressing the previous trade-offs between effective treatment and patient comfort.
Why Enovis (ENOV) Is Up 9.6% After Beating Q1 Targets And Enhancing Incentive Plan Alignment
Enovis (ENOV) shares increased by 9.6% after the company exceeded Q1 2026 revenue and adjusted EPS targets and reaffirmed its full-year outlook. Shareholders also approved amendments to the incentive plan, aligning leadership rewards with operational progress. This performance and enhanced incentives are shaping a new investment narrative, despite historical challenges like losses and weak returns on invested capital.
A Look At Enovis (ENOV) Valuation As Shares Rebound And Long Term Returns Lag
Enovis (ENOV) shares have recently rebounded, showing an increase of about 4% over the past day and 5% over the past week, though year-to-date and longer-term returns remain weak. Despite lingering caution from investors, Simply Wall St's analysis suggests Enovis is undervalued by 46.8%, with a fair value estimate of $44.73 compared to its current price of $23.78. This valuation is driven by expectations of growth, rising profitability from next-generation technologies, and a higher future earnings multiple, while acknowledging risks like integration challenges from recent acquisitions.
3 Reasons ENOV is Risky and 1 Stock to Buy Instead
Enovis (ENOV) shares have dropped significantly, contrasting with the S&P 500's gains. The company is deemed risky due to spiraling revenue, negative return on invested capital from previous growth initiatives, and a continued decline in ROIC from new investments. The article suggests Enovis doesn't pass a quality test and recommends investors consider alternative stocks.
ENOV - Enovis Corp Stock Price and Quote
This page provides a detailed overview of Enovis Corp (ENOV) stock, including its latest price, financial metrics, analyst ratings, and recent news. It also features insider trading activity for key personnel within the company.
